Ken Griffin Delcath Systems, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 30,100 shares of DCTH stock, worth $371,434. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,100
Previous 12,700
137.01%
Holding current value
$371,434
Previous $149,000
157.05%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding DCTH
# of Institutions
102Shares Held
12.1MCall Options Held
79KPut Options Held
53.3K-
Vanguard Group Inc Valley Forge, PA1.39MShares$17.2 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$10 Million0.26% of portfolio
-
Vivo Capital, LLC Palo Alto, CA750KShares$9.26 Million2.59% of portfolio
-
Exodus Point Capital Management, LP New York, NY699KShares$8.63 Million0.09% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$6.88 Million0.0% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $106M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...